Evaluation metrics for neural architectures are shifting from language fluency toward hard physical sciences. On November 7, 2026, OpenAI’s research division unveiled BioBasicsBench, an evaluation suite containing 100 complex, practical tasks derived from wet-lab molecular biology.
The benchmark compels models to analyze raw experimental output, pinpoint cloning anomalies, parse cytometry, and acknowledge evidentiary gaps. OpenAI’s flagship GPT-6 Astra scored 66.7%, outperforming GPT-5.6 Sol (43.8%). For the B2B biotech and pharmaceutical sectors, this serves as a pivotal milestone: AI agents are transitioning from summarizers of literature into autonomous analytical assistants capable of managing wet-lab workflows, radically accelerating drug-discovery R&D cycles.
Sources: OpenAI Research | Advance Intelligence
Wet-Lab Testing: OpenAI Releases BioBasicsBench to Benchmark AI in Biology Labs
